Please Note: Study Extended for Five Dogs

As of 2-10-2015, additional secured funding will allow us to enroll 5 more dogs onto this clinical trial. Please contact us if you think your dog might qualify for the study.

Purpose of study: The purpose of this pilot study is to evaluate whether vaccination with a new tumor-targeting cancer vaccine (ADXS31-164) combined with radiation therapy can decrease bone cancer pain and prolong overall survival in dogs with OSA.

Eligibility criteria:

Dogs with suspected early OSA based on breed, clinical signs and radiographs
Dogs that are otherwise systemically healthy (no cancer spread to the lungs, no other health problems such as kidney disease, liver disease, heart disease etc)
Dogs that are not candidates for amputation (either because they are too big or have concurrent orthopedic problems such as hip dysplasia)
Dogs that have not received prior treatment for OSA

Procedures covered by the study:

1.    Physical examinations at each study visit (all visits are at the University of Pennsylvania School of Veterinary Medicine).
2.    Bone biopsy.
3.    Two (2) doses of radiation therapy under general anesthesia.
4.    Blood tests, urinalysis and immune evaluation at enrollment and at each vaccination.
5.    Three complete staging evaluations including blood tests, urinalysis, limb radiographs, chest radiographs, ECG, and echocardiography.
6.    Eight doses of Listeria monocytogenes huHer-2/neu recombinant vaccine.
7.    Three days of antibiotics following each vaccine administration.
8.    The treatment of any toxicity directly resulting from vaccine administration.

Please note: As of 2-10-2015, additional secured funding will allow us to enroll 5 more dogs onto this clinical trial. Please contact us if you think your dog might qualify for the study.

 Contact: Aliza Hildebrand Schmidt, MS, Clinical Research Coordinator
Phone: 215-746-2239
Email: alizasch@vet.upenn.edu